CENTREXION THERAPEUTICS CORPORATION (a Delaware corporation) [•] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • November 5th, 2018 • Centrexion Therapeutics Corp • Pharmaceutical preparations • New York
CENTREXION THERAPEUTICS CORPORATION INDEMNIFICATION AGREEMENTIndemnification Agreement • November 5th, 2018 • Centrexion Therapeutics Corp • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of , 20[18] between Centrexion Therapeutics Corporation, a Delaware corporation (the “Company”), and [Name] (“Indemnitee”).
ContractCentrexion Therapeutics Corp • November 5th, 2018 • Pharmaceutical preparations • Delaware
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENTAdoption Agreement • November 5th, 2018 • Centrexion Therapeutics Corp • Pharmaceutical preparations • Delaware
THIS THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (this “Agreement”), is made as of December 18, 2017, by and among Centrexion Therapeutics Corporation, a Delaware corporation (the “Company”), the Key Holders (as defined below), each Holder (as defined below) listed on Schedule I hereto (each Key Holder and Holder, a “Stockholder” and collectively, the “Stockholders”) and each stockholder of the Company that becomes a party to this Agreement in accordance with Section 6.9 hereof (each, an “Additional Stockholder”). Capitalized terms used in this Agreement but not otherwise defined have the meanings set forth in Sections 1.1 and 1.2.
Re: Executive Employment AgreementEmployment Agreement • November 5th, 2018 • Centrexion Therapeutics Corp • Pharmaceutical preparations • New York
This letter agreement (the “Agreement”) confirms the terms and conditions of your employment with Centrexion Corporation (the “Company”):
Confidential Treatment Requested Centrexion Therapeutics Corporation PATENT ASSIGNMENT AND LICENSING AGREEMENT dated NOVEMBER 11, 2015 by and between BOEHRINGER INGELHEIM INTERNATIONAL GMBH hereinafter “BII” and CENTREXION THERAPEUTICS CORPORATION...Patent Assignment and Licensing Agreement • November 5th, 2018 • Centrexion Therapeutics Corp • Pharmaceutical preparations
Boehringer Ingelheim International GmbH (“BII”), a German limited liability company, with offices at Binger Straße 173, 55216 Ingelheim am Rhein, Germany; and
CENTREXION THERAPEUTICS CORPORATION WARRANT TO PURCHASE SHARESCentrexion Therapeutics Corp • November 5th, 2018 • Pharmaceutical preparations • New York
This Warrant is issued to Mr. Zhang Xuefeng by Centrexion Therapeutics Corporation, a Delaware corporation (the “Company”), as of December 30, 2016 (the “Effective Date”), in connection with the holder’s provision of consulting services to the Company pursuant to the consulting agreement, dated as of December 30, 2016 (the “Consulting Agreement.”)
Confidential Treatment Requested Centrexion Therapeutics Corporation AMENDMENT #1 TO PATENT ASSIGNMENT AND LICENSING AGREEMENTPatent Assignment and Licensing Agreement • November 5th, 2018 • Centrexion Therapeutics Corp • Pharmaceutical preparations
This Amendment No. 1 (“Amendment No. 1”) to the Patent Assignment and Licensing Agreement by and between Boehringer Ingelheim International GmbH (“BII”) and Centrexion Therapeutics Corporation (“CENTREXION”), dated November 11, 2015, (the “Agreement”) is entered into effective as of January 29, 2018.
